Bischoff-Ferrari Heike A, Willett Walter C, Wong John B, Giovannucci Edward, Dietrich Thomas, Dawson-Hughes Bess
Department of Nutrition, Harvard School of Public Health, Boston, Mass 02115, USA.
JAMA. 2005 May 11;293(18):2257-64. doi: 10.1001/jama.293.18.2257.
The role and dose of oral vitamin D supplementation in nonvertebral fracture prevention have not been well established.
To estimate the effectiveness of vitamin D supplementation in preventing hip and nonvertebral fractures in older persons.
A systematic review of English and non-English articles using MEDLINE and the Cochrane Controlled Trials Register (1960-2005), and EMBASE (1991-2005). Additional studies were identified by contacting clinical experts and searching bibliographies and abstracts presented at the American Society for Bone and Mineral Research (1995-2004). Search terms included randomized controlled trial (RCT), controlled clinical trial, random allocation, double-blind method, cholecalciferol, ergocalciferol, 25-hydroxyvitamin D, fractures, humans, elderly, falls, and bone density.
Only double-blind RCTs of oral vitamin D supplementation (cholecalciferol, ergocalciferol) with or without calcium supplementation vs calcium supplementation or placebo in older persons (> or =60 years) that examined hip or nonvertebral fractures were included.
Independent extraction of articles by 2 authors using predefined data fields, including study quality indicators.
All pooled analyses were based on random-effects models. Five RCTs for hip fracture (n = 9294) and 7 RCTs for nonvertebral fracture risk (n = 9820) met our inclusion criteria. All trials used cholecalciferol. Heterogeneity among studies for both hip and nonvertebral fracture prevention was observed, which disappeared after pooling RCTs with low-dose (400 IU/d) and higher-dose vitamin D (700-800 IU/d), separately. A vitamin D dose of 700 to 800 IU/d reduced the relative risk (RR) of hip fracture by 26% (3 RCTs with 5572 persons; pooled RR, 0.74; 95% confidence interval [CI], 0.61-0.88) and any nonvertebral fracture by 23% (5 RCTs with 6098 persons; pooled RR, 0.77; 95% CI, 0.68-0.87) vs calcium or placebo. No significant benefit was observed for RCTs with 400 IU/d vitamin D (2 RCTs with 3722 persons; pooled RR for hip fracture, 1.15; 95% CI, 0.88-1.50; and pooled RR for any nonvertebral fracture, 1.03; 95% CI, 0.86-1.24).
Oral vitamin D supplementation between 700 to 800 IU/d appears to reduce the risk of hip and any nonvertebral fractures in ambulatory or institutionalized elderly persons. An oral vitamin D dose of 400 IU/d is not sufficient for fracture prevention.
口服维生素D补充剂在预防非椎体骨折中的作用和剂量尚未明确。
评估补充维生素D对预防老年人髋部骨折和非椎体骨折的有效性。
使用MEDLINE和Cochrane对照试验注册库(1960 - 2005年)以及EMBASE(1991 - 2005年)对英文和非英文文章进行系统评价。通过联系临床专家以及检索在美国骨与矿物质研究学会(1995 - 2004年)上发表的参考文献和摘要来识别其他研究。检索词包括随机对照试验(RCT)、对照临床试验、随机分配、双盲法、胆钙化醇、麦角钙化醇、25 - 羟基维生素D、骨折、人类、老年人、跌倒和骨密度。
仅纳入对60岁及以上老年人进行口服维生素D补充剂(胆钙化醇、麦角钙化醇)联合或不联合钙剂与钙剂补充或安慰剂对比,且研究髋部或非椎体骨折的双盲RCT。
由2名作者使用预定义的数据字段独立提取文章,包括研究质量指标。
所有汇总分析均基于随机效应模型。5项关于髋部骨折的RCT(n = 9294)和7项关于非椎体骨折风险的RCT(n = 9820)符合我们的纳入标准。所有试验均使用胆钙化醇。在预防髋部和非椎体骨折的研究中均观察到研究间的异质性,在分别汇总低剂量(400 IU/d)和高剂量维生素D(700 - 800IU/d)的RCT后异质性消失。与钙剂或安慰剂相比,维生素D剂量为700至800 IU/d可使髋部骨折的相对风险(RR)降低26%(3项RCT,共5572人;汇总RR,0.74;95%置信区间[CI],0.61 - 0.88),使任何非椎体骨折的相对风险降低23%(5项RCT,共6098人;汇总RR,0.77;95% CI,0.68 - 0.87)。对于维生素D剂量为400 IU/d的RCT未观察到显著益处(2项RCT,共3722人;髋部骨折汇总RR,1.15;95% CI,0.88 - 1.50;任何非椎体骨折汇总RR,1.03;95% CI,0.86 - 1.24)。
每天口服700至800 IU的维生素D似乎可降低非卧床或机构养老老年人髋部骨折和任何非椎体骨折的风险。每天口服400 IU的维生素D剂量不足以预防骨折。